Telix QSAM Inc (QSAM)

[copleybmt]

Some buyers today! Not much selling in the 20 and 30s anymore. Are the 40s next to go? I hope so as this should get fun by Christmas.

[trader_ron]

$QSAM Chart- looks good
https://www.barchart.com/stocks/quotes/QSAM/overview

[trader_ron]

QSAM just brought on the world renowned and award winning Dr. Richard K. Burt to their Advisory Board. Here Dr. Burt is featured on CBS This Morning for his ground breaking work with MS.

This is a sleeping giant, low float and market cap with top notch management.

[Wrangler1]

The company’s IR needs to get to work and get more eyes on this ticker or get some partners behind them. Orphan drug designation AND IND clearance by the FDA. With the news they have released this should not be a $15M cap.

[trader_ron]

$QSAM The FDA cleared QSAMs investigational new drug IND application which allows the Company to commence Phase 1 clinical trials and the dosing of patients with bone cancer. https://qsambio.com/

[trader_ron]

The FDA cleared $QSAM investigational new drug IND application which allows the Company to commence Phase 1 clinical trials and the dosing of patients with bone cancer.

[trader_ron]

You will have a hard time finding any other biotech/biopharma in Phase 1 with less than $100 million in market cap.

[trader_ron]

$QSAM Radiopharmaceutical companies are getting huge interest from investors. Bayer, the giant German drug company, just acquired two of them. https://www.biopharmadive.com/news/bayer-noria-psma-prostate-cancer/601211/

[trader_ron]

A few weeks before QSAM received Orphan Drug Approval market cap - fully diluted - is $16.3 million.

[trader_ron]

A few weeks before QSAM received Orphan Drug Approval market cap - fully diluted - is $16.3 million.

[Gentlemen Prefer Bonds]

I don't know for sure, but I talked to the investor relations department and it sounds like there might be 200,000 to 300,000. After they are gone I think QSAM goes back above $1.

[trader_ron]

QSAM just brought on the world renowned and award winning Dr. Richard K. Burt to their Advisory Board. Here Dr. Burt is featured on CBS This Morning for his ground breaking work with MS.

[trader_ron]

Up 16%

[trader_ron]

$QSAM = UnderValued

[trader_ron]

QSAM The overall market for Radiopharmaceuticals is expected to exceed US$6.1 billion. The rising prevalence of cancer and cardiovascular diseases are the main factors driving the radiopharmaceuticals market.

[trader_ron]

Breakout Chart-
https://www.barchart.com/stocks/quotes/QSAM/overview

[trader_ron]

QSAM Biosciences, Inc. is developing next generation nuclear medicines for the treatment of cancer and related diseases and conditions.

QSAM’s initial technology is Samarium-153 DOTMP, aka CycloSam®, a clinical-staged bone targeting radiopharmaceutical? developed by IsoTherapeutics Group LLC, leaders in the nuclear medicine space who also developed FDA-approved and commercially available Quadramet® (Samarium-153 EDTMP), indicated for pain palliation. CycloSam was assigned to IsoTherapeutics Group’s subsidiary, IGL Pharma, Inc.

[trader_ron]

Tremendous upside, word is getting out.

[copleybmt]

This stock has huge upside potential!

[trader_ron]

QSAM Biosciences Receives Patents in Japan and Canada; Strengthens Licensed IP Portfolio in Key Markets
#UnderValued #otcmarkets #nasdaq #investors
https://www.otcmarkets.com/stock/QSAM/news/QSAM-Biosciences-Receives-Patents-in-Japan-and-Canada-Strengthens-Licensed-IP-Portfolio-in-Key-Markets?id=315852

[trader_ron]

OTCQB Symbol QSAM

Current Price $0.45

Shares Outstanding 27,497,850

Restricted Shares 22,180,128

Unrestricted 5,317,722

Held at DTC 5,241,361

Float 4,630,181

Market Cap $11 million

52 Week Trading Range

52-Week Low $0.20

52-Week High $2.10

[trader_ron]

$QSAM QSAM Biosciences Announces FDA Clearance of IND for Samarium-153 DOTMP (CycloSam®), an Investigational Radiopharmaceutical for the Treatment of Bone Cancer

[trader_ron]

Watching for news, time for this one to move higher

[RandyKCMO]

An Example I’d what I’m talking about.

News Release Today: QSAM Biosciences Seeks to Expand Radiochemical Assets; Signs Option Agreement to License its Second Promising Cancer Therapy

Austin, Texas, March 17, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences, Inc. (OTCQB: QSAM) announced today that it has signed an Exclusive Option Agreement with IsoTherapeutics Group, LLC to allow the Company a 120-day period to perform diligence and negotiate a worldwide, exclusive license agreement for a pre-clinical staged radiochemical therapy called BetaBrach™.

BetaBrach is a brachytherapy, a cancer treatment where radioactive implants are inserted directly into diseased tissue to eradicate the target tumor. BetaBrach uses beta radiation (Yyttrium-90) chemically formulated to significantly reduce migration to non-targeted healthy tissue. It has been used extensively in numerous small animal laboratory models of cancer as well as in the University of Missouri’s College of Veterinary Medicine to treat large animals with naturally occurring tumors with very promising results. Such therapy could be used to treat many types of cancer in humans, including breast and prostate.

“This is an important step in our strategy to build a pipeline of radiochemical assets to develop and commercialize for critical and high unmet medical needs, such as cancer,” stated Douglas R. Baum, the Company’s CEO and Co-Founder. “Delivering a precise and personalized dose of BetaBrach directly to the targeted tumor has the potential to be an optimal treatment option for a broad base of cancer patients, as we believe it can also prevent the debilitating side effects and systemic toxicity associated with current treatments such as chemotherapy.”

The option to license BetaBrach follows the Company’s strategy used to acquire the worldwide rights to CycloSam® (Samarium-153 DOTMP) in 2020 from an IsoTherapeutics affiliated company whose founders created Quadramet® (Samarium-153-EDTMP), one of the first FDA approved and commercially available radiopharmaceuticals.






https://www.otcmarkets.com/stock/QSAM/news/QSAM-Biosciences-Seeks-to-Expand-Radiochemical-Assets-Signs-Option-Agreement-to-License-its-Second-Promising-Cancer-Ther?id=294067

[RandyKCMO]

I think this multiplies the potential value of QSAM as additional drugs and treatments are developed and put forward.

[RandyKCMO]

Exactly. I’ve come to the same conclusion. Check out this April 28, 2021 powers release… check out the bold print…

News 4/28/2020 Q2Earth’s Bioscience Subsidiary, QSAM Therapeutics, Signs License for Promising Drug to Treat Bone Cancer.

Palm Beach, FL, April 28, 2020 (GLOBE NEWSWIRE) -- Q2Earth, Inc. (OTCQB: QPWR) (the “Company” or “Q2”) announced today that its wholly-owned subsidiary, QSAM Therapeutics Inc. (“QSAM”), has signed a Patent and Technology License Agreement and Trademark Assignment with IGL Pharma, Inc. (“IGL”).
The License Agreement provides QSAM with exclusive, worldwide and sub-licensable rights for up to 20 years to all of IGL’s patents, product data and knowhow with respect to Samaium-153 DOTMP (the “Technology”), a clinical stage novel radiopharmaceutical meant to treat different types of bone cancer and related diseases. The Technology was originally developed by IGL’s affiliated company ISO Therapeutics Group, LLC (“ISO”) whose founders created Quadramet® (Samarium-153-EDTMP), one of the first commercial radiopharmaceuticals. The License Agreement also provides QSAM a first right of refusal for other IGL/ISO technologies.

Initial indications for Samarium-153 DOTMP include bone marrow ablation, a pre-transplant procedure used to treat various diseases including cancer, immune system disorders and blood diseases including sickle cell disease. According to the U.S. Health Resources & Services Administration, approximately 23,000 transplant procedures were performed in 2018, representing a market in the United States of over $1 Billion per year. Other important indications for the Technology include pediatric osteosarcoma, a devastating form of bone cancer afflicting children, adult osteosarcoma, as well as a broader market in metastasized adult and pediatric bone cancers.
Douglas Baum, a Director of the Company who has been named President and CEO of the subsidiary QSAM, stated: “We thank the IGL and ISO team for entrusting us to advance their novel technology to commercialization. We believe we will be able to enter clinical trials this year and, in short order, demonstrate the efficacy and safety of this radiopharmaceutical.”
“For Q2 shareholders, our license with IGL is an important milestone in our 2020 strategic plan which includes securing new technologies in the broader biosciences sector. This licensed technology provides a foundation to bring in new capital and reduce our current debt burden, which may include an investment and purchase of assets and contracts by our affiliated company, Earth Property Holdings. Our goal is to advance this plan in the coming months,” continued Mr. Baum, a senior executive with over 28 years of experience in biosciences and drug and medical device commercialization.
About QSAM: QSAM Therapeutics Inc., a newly formed subsidiary of Q2Earth, holds the worldwide license for Samaium-153 DOTMP, a clinical stage novel radiopharmaceutical meant to treat different types of bone cancer and related diseases. This technology uses low specific activity Samarium-153 (resulting in far less europium) and DOTMP, a chelator which is believed to eliminate off-target migration and targets high bone turn over making it an ideal agent to treat osteosarcoma, bone metastases and to perform bone marrow ablation. Sm-153 DOTMP has been cleared by the FDA under an investigator initiated IND to commence human dosing of cancer patients.
About Q2Earth: Q2Earth currently manages compost and soil manufacturing facilities, and holds a license for an all-natural soil health supplement called ABS. The Company is pursuing additional licensing opportunities in biotech and biosciences that will expand its intellectual property portfolio and create new business opportunities.

https://www.otcmarkets.com/stock/QPWR/news/Q2Earths-Bioscience-Subsidiary-QSAM-Therapeutics-Signs-License-for-Promising-Drug-to-Treat-Bone-Cancer?id=260331

[trader_ron]

The overall market for Radiopharmaceuticals is expected to exceed US$6.1 billion. The rising prevalence of cancer and cardiovascular diseases are the main factors driving the radiopharmaceuticals market.

QSAM Biosciences, Inc. (“QSAM”) is comprised of industry experts formed to acquire the rights to and seek commercialization of Samarium-153 DOTMP, aka CycloSam®, a bone targeting radiopharmaceutical? from IsoTherapeutics Group.

IsoTherapeutics’ scientists, leaders in the development of radiopharmaceuticals, also developed FDA approved and commercially released Quadramet® (Samarium-153 EDTMP), indicated for pain palliation.

CycloSam® shares the same FDA approved radioisotope as Quadramet®, but utilizes a novel chelate that had demonstrated preliminary increased efficacy and decreased side effects in animal models.

CycloSam® is cleared by the FDA under an investigator IND to commence human dosing immediately in patients with osteosarcoma and bone metastasis.

The study protocol, Principal Investigator, 1 clinical site and manufacturing plan are all finalized and the clinical trial is ready to commence. Additional sites are proposed to be coming online in the coming months to participate in the clinical trial.

CycloSam® is also cleared by the FDA under a second single-patient IND to perform bone marrow ablation prior to allogenic marrow transplantation (BMA/T).

Fifteen (15) patents under prosecution in the US and internationally; two of which have been issued.

[RandyKCMO]

Been following since merger. Experienced management with successful record Of dozens of drugs approved through FDA.

Plus, you have to dig to see it, but their agreement with the drug developer entitles them to right of first refusal to license all future drugs they develop.

Incredible potential for becoming a buy out candidate.

[trader_ron]

$QSAM Boom! QSAM Biosciences (QSAM) Cleared By FDA For Phase 1 on Cyclosam p0.vresp.com/fnR1oK #vr4smallbiz

[trader_ron]

$QSAM @ 0.3600 - QSAM Biosciences gets FDA clearance for early-stage CycloSam bone cancer trials

[trader_ron]

Looking sweet

[ChuckFinley305]

You can buy as many as you want at 50% off... though I would wait until the price corrects itself from this news.. or even better, wait until all the shares coming due are sold.

-Chuck

[copleybmt]

I already bought the 24 cent shares a while ago could not get many though.

[ChuckFinley305]

Contact QSAM directly, I bet they will sell you shares at a 50% discount if you are OK with holding on to it for 6 months.

-Chuck

[copleybmt]

Don't you think most of those shares are gone over the past two months?

[Gentlemen Prefer Bonds]

According to SEC filings maybe 500,000 shares. Looks like it was all purchased around $.25

[RandyKCMO]

The 10K bid at $.49 was pretty encouraging.

Too bad someone tapped it… Else we might be trading about 50 cents.

[copleybmt]

UP 36% and 8 IHub posts! Ihubbers sleeping at the wheel.

[copleybmt]

Most on Ihub do not mess with stocks that are over 25 cents so I don't see breakout board either. I look at percentages verses really cheap prices

[copleybmt]

How much cheap stock and at what price? Where did you find this info?

[Gentlemen Prefer Bonds]

No, because there are a handful of idiots who have cheap stock. Once they arre out of the way the stock will perform much better.

[copleybmt]

Do you think this could make the breakout board today?

[copleybmt]

This is the starting gun going off in a marathon race. Game On!

[RandyKCMO]

Here's the Release: QSAM Biosciences Announces FDA Clearance of IND for Samarium-153 DOTMP (CycloSam®), an Investigational Radiopharmaceutical for the Treatment of Bone Cancer

Press Release | 08/25/2021
Austin, TX, Aug. 25, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation nuclear medicines, including Samarium-153 DOTMP (CycloSam®), for the treatment of cancer and related diseases and conditions, announced that the U.S. Food and Drug Administration (FDA) has cleared QSAM’s investigational new drug (IND) application which allows the Company to commence Phase 1 clinical trials and the dosing of patients with bone cancer.

“This IND clearance is another major milestone for QSAM and the advancement of CycloSam. We expect to commence our Phase 1 open-label dose escalation trial in bone cancer patients by the end of this year. These trials will be intended to investigate the efficacy, safety, tolerability and pharmacokinectics of CycloSam to establish the optimal dose for pivotal Phase 2/3 clinical trials,” stated the Company’s Co-Founder and CEO, Douglas R. Baum. “The clearance of our IND also continues to validate our data-driven approach in oncology drug development and sets the stage for additional aggressive efforts we are undertaking in pediatric and adult cancer therapies.”

CycloSam is expected to be a significantly improved formulation of a previously FDA-approved radiopharmaceutical. This novel drug candidate utilizes both a more efficient method of isotope manufacturing and an advanced chelation technology which may potentially allow for repeated dosing of patients with bone cancer in an effort to halt or reverse tumor growth.

About QSAM Biosciences:
QSAM Biosciences, Inc. is developing next-generation nuclear medicines for the treatment of cancer and related diseases. QSAM’s initial technology is CycloSam® (Samarium-153 DOTMP), a clinical-stage bone targeting radiopharmaceutical developed by IsoTherapeutics Group LLC, pioneers in the nuclear medicine space who also developed a previous FDA-approved and commercially available radiopharmaceutical product indicated for pain palliation. QSAM is led by an experienced executive team and Board of Directors that have completed dozens of FDA approvals and multiple successful biotech exits.

CycloSam® has demonstrated preliminary safety and efficacy in animal studies and a single patient FDA-cleared human trial successfully performed in 2020. This nuclear technology uses low specific activity Samarium-153 (resulting in far less europium-154 impurity) and DOTMP, a chelator which is believed to eliminate off-target migration and targets sites of high bone turn over making it an ideal agent to treat primary and secondary bone cancers. Since CycloSam® has the ability to deliver targeted radiation selectively to the skeletal system, it is also believed to be an effective agent to perform bone marrow ablation as pre-conditioning for bone marrow transplantation, and in procedures to reduce external beam radiation to bone tumors. This multi-patented drug candidate utilizes an FDA approved radioisotope combined with a novel chelant that has demonstrated preliminary increased efficacy and decreased side effects in animal models and veterinary treatment of bone cancer in dogs. Further, CycloSam® utilizes a streamlined, just-in-time manufacturing process that is already in place. Given these factors, management believes there is a strong pathway to commercialization for CycloSam®.


https://www.otcmarkets.com/stock/QSAM/news/QSAM-Biosciences-Announces-FDA-Clearance-of-IND-for-Samarium-153-DOTMP-CycloSam-an-Investigational-Radiopharmaceutical-f?id=317971

[TradeForProfits]

yes, this is great $QSAM news FDA Clearance of IND for Samarium-153 DOTMP (CycloSam®), an Investigational Radiopharmaceutical for the Treatment of Bone Cancer https://finance.yahoo.com/news/qsam-biosciences-announces-fda-clearance-130000396.html

[Wrangler1]

Great news!!!!!

[Gentlemen Prefer Bonds]

Wooohooo! QSAM is in Phase 1 with the FDA! The valuation just went up! https://finance.yahoo.com/news/qsam-biosciences-announces-fda-clearance-130000396.html

[ChuckFinley305]

Nope, not at all.


Just as the news of getting an international patent did, this news caused little or no action in trading. The only way the patent and this Orphan designation becomes valuable is if the drug succeeds. They are still so early in the development that the risk to invest isn't worth the potential reward as the possibly of utter failure is still very high.

They need a PR stating a huge pharma company signed on to help co-develop if they want gain attention from the "masses" of investors. Otherwise the reality is that this is a company with NO product and NO history of ever creating a product. Their script has been written and flipped three times now.. the previous 2 times left investors holding the bag while the upper management cashed checks from the capital raised.

It still makes me sick to think this company with no official full time employees was able to get several hundred thousands of dollars in Covid relief funding.

-Chuck

[copleybmt]

We should see this run when the masses find the news

[RandyKCMO]

Pretty great day for the stock so far...
So far our Volume Weighted Average Price (VWAP) is just under 41 cents.


I think it's clear that we're heading for higher ground.

Basically, this is asking??? Any sellers here?? Come on Sellers!!